The effect of oral L-carnitine supplementation on polycystic ovary syndrome

Phase 3

Recruiting

• Conditions: Polycystic Ovarian Syndrome.; Polycystic Ovarian Syndrome; E28.2

• Registration Number: IRCT20191016045131N1
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 62

Inclusion Criteria

18-45 years old women referred to Yazd Diabetes Center
Polycystic ovary syndrome based on Rotterdam diagnostic criteria
Body Mass Index 25 and over
interested in participation in the study
Taking usual treatment of PCOS

Exclusion Criteria

Smoking
Suffering from diabetes or thyroid disease
Having a special diet for the past three months
Weight-loss medication, hormone or ovulation stimulant use

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Insulin Kit.;Fasting blood sugar. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;Sex hormone-binding globulin. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: kit.;Triglyceride. Timepoint: At the beginning and at the end of the study (120 days after). Method of measurement: Blood test.;Cholesterol. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;HDL. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;LDL. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test.;HOMA IR. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: By formula using fasting glucose and insulin.